Key Highlights
- Junevity raises $10M in seed funding led by Goldcrest Capital and Godfrey Capital.
- RESET platform uses AI and human data to identify transcription factors and develop siRNA therapeutics.
- Initial targets include Type 2 diabetes, obesity, and frailty, with preclinical data showing promising results.
- Therapeutic candidates offer long dosing intervals (3-12 months) for better patient compliance.
- Founded at UCSF, led by top scientists and biotech leaders.
Source: Business Wire
Notable Quotes
- “Junevity’s RESET platform is a big idea that could broadly impact human health by addressing aging at the cellular level.” – Dr. John Hoekman, Co-founder & CEO at Junevity
- “My research at UCSF showed the power of targeting transcription factors to restore aged human cells back to health.” – Dr. Janine Sengstack, Co-founder & CSO at Junevity
- “The Junevity team has a novel approach, incredible early data, and tremendous potential to treat metabolic and age-related diseases.” – Brent Saunders, CEO & Chairman at Bausch + Lomb
Why This Matters
Aging-related diseases like diabetes, obesity, and frailty impact billions globally. Junevity’s AI-powered RESET platform pioneers a new class of siRNA therapeutics designed to reverse cell damage and extend human healthspan. With strong preclinical data and a world-class team, this funding positions Junevity to lead the next generation of longevity therapeutics.
